Dublin, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The "Global Therapeutic Vaccines Market (2023-2028) by Product, Disease Indication, Technology, End User, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
The Global Therapeutic Vaccines Market, estimated at USD 9.09 billion in 2023, is projected to reach USD 11.98 billion by 2028, boasting a Compound Annual Growth Rate (CAGR) of 5.68%. This report provides a comprehensive exploration of the market, delving into challenges, innovations, and key segmentations that drive the industry's dynamics.
Market Challenges: Adverse Effects and Regulatory Hurdles
One of the primary challenges in the Therapeutic Vaccines (PAH) market is the occurrence of drug-related adverse effects. While these vaccines are designed to improve patient outcomes, they can lead to side effects such as headaches, nausea, diarrhea, fluid retention, liver damage, and potential drug interactions. Effectively managing and minimizing these adverse effects is crucial to ensure patient safety and treatment adherence.
Rising Demand Driven by Disease Prevalence
The increasing prevalence of diseases like cancer, HIV, and autoimmune disorders has heightened the demand for therapeutic vaccinations as viable treatment options. This surge in demand fuels research, development, and commercialization of therapeutic vaccines to address these widespread health concerns.
Biologics Take the Spotlight
Biologics, including therapeutic vaccines, offer targeted and personalized therapeutic options. As the healthcare sector embraces precision medicine, the demand for biologics, especially therapeutic vaccines, continues to rise, giving them a larger market share compared to other treatment modalities.
Innovative Vaccines Open New Avenues
Innovative vaccines, such as peptide-based therapeutic vaccines and advanced pneumococcal vaccines, introduce novel treatment options and address unmet medical needs. These innovations carve out new markets by providing more effective and targeted solutions for various diseases, thus expanding their market share.
Technological Advancements Enhance Efficacy
Continual technological advancements, encompassing improved vaccination delivery systems, adjuvants, and manufacturing processes, enhance the safety and efficacy of therapeutic vaccines. These advancements attract investments and stimulate market growth, although their market share may be relatively lower than newer vaccines that introduce entirely new therapeutic approaches.
Market Entry Challenges for Smaller Players
The substantial expenditure required for research, clinical trials, and vaccine production can pose an entry barrier for smaller companies, limiting the number of competitors and influencing the market's overall size.
Regulatory Complexities Slow Market Entry
Complex regulatory processes and stringent safety criteria in vaccine licensing may delay market entry, reducing the market share of therapeutic vaccines. Approval and market access are often granted to well-established candidates, making it challenging for new entrants.
Slow Clinical Trial Processing Hinders Market
Slow processing of clinical trials for specific vaccines extends the time required to bring new therapeutic vaccines to the market. This delay hampers the availability of new treatments for patients and affects rapid responses to emerging health threats.
Market Segmentations: A Detailed Insight
- Product: The market is classified into Autoimmune Disease Vaccines, Neurological Disease Vaccines, Cancer Vaccines, Infectious Disease Vaccines, and Other Products, with Cancer Vaccines holding a dominant market share.
- Disease Indication: Segments include DTP, Dengue, Hepatitis, Human Papilloma Virus, Influenza, MMR, Polio, Varicella, and Others. Influenza vaccines hold the largest market share due to routine administration for seasonal flu prevention.
- Technology: Allogeneic Vaccine and Autologous Vaccine are the key segments, with Allogeneic Vaccines claiming a larger market share.
- End User: The market distinguishes between Adults and Pediatrics, with Adults occupying a significant market share.
- Geography: The Americas lead in market share due to superior healthcare infrastructure and investment in research and development.
Recent Developments:
- Janssen is seeking approval from the European Medicines Agency (EMA) for a single tablet therapeutic vaccine treatment, providing a more convenient option for PAH patients.
- Merck's blood vessel disorder drug has succeeded in a late-stage study, showcasing the continual innovation in therapeutic vaccines.
Company Profiles: The report includes detailed analysis and financial performance data for key market competitors, such as Agenus, Argos Therapeutic, Dendreon Corp, Pfizer, and more. These profiles provide insights into their recent developments and competitive scenarios.
Countries Studied: The study covers countries in the Americas, Europe, Middle-East & Africa, and Asia-Pacific, offering a global perspective on the therapeutic vaccines market.
Competitive Quadrant: This proprietary tool assesses and categorizes market players based on their Industry Position and Market Performance scores. It considers factors like financial performance, growth strategies, innovation, product launches, and market share to classify companies into four categories.
Ansoff Analysis: The report employs the Ansoff Matrix to design growth strategies for companies, categorizing them into Market Development, Market Penetration, Product Development, and Diversification strategies. The matrix also aids in risk analysis, understanding the risks associated with each approach.
SWOT Analysis and Growth Strategies: The report conducts a SWOT analysis of the industry and its players, offering suitable strategies for market growth.
In conclusion, the Global Therapeutic Vaccines Market presents significant opportunities and challenges. With a focus on innovation, precision medicine, and addressing prevalent diseases, the market is set to grow. However, regulatory complexities and clinical trial delays necessitate a strategic approach for success.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 128 |
| Forecast Period | 2023-2028 |
| Estimated Market Value (USD) in 2023 | $9.09 Billion |
| Forecasted Market Value (USD) by 2028 | $11.98 Billion |
| Compound Annual Growth Rate | 5.6% |
| Regions Covered | Global |
Key Topics Covered
1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Analyst Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Impact Analysis
4.2 Drivers
4.2.1 Rising Prevalence of Diseases Such as Chronic and Infectious Diseases
4.2.2 Rising Demand for Biologics and Drugs for Targeted Diseases
4.3 Restraints
4.3.1 Huge Capital Expenditures Associated with Vaccine Development
4.3.2 Stringent Government Regulations for the Approval of Vaccines
4.4 Opportunities
4.4.1 Introduction of novel Vaccines Such as Peptide-Based Therapeutic Vaccines, and Pneumococcal Vaccines
4.4.2 Technological Advancements
4.5 Challenges
4.5.1 Slow Processing of Clinical Trials to produce some Vaccines
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 PESTLE Analysis
5.4 Impact of COVID-19
5.5 Ansoff Matrix Analysis
6 Global Therapeutic Vaccines Market, By Product
6.1 Introduction
6.2 Autoimmune Disease Vaccines
6.3 Neurological Disease Vaccines
6.4 Cancer Vaccines
6.5 Infectious Disease Vaccines
6.6 Other Products
7 Global Therapeutic Vaccines Market, By Disease Indication
7.1 Introduction
7.2 DTP
7.3 Dengue
7.4 Hepatitis
7.5 Human Papilloma Virus
7.6 Influenza
7.7 MMR
7.8 Polio
7.9 Varicella
7.10 Others (Pneumococcal Disease, Meningococcal Disease, etc)
8 Global Therapeutic Vaccines Market, By Technology
8.1 Introduction
8.2 Allogeneic Vaccine
8.3 Autologous Vaccine
9 Global Therapeutic Vaccines Market, By End User
9.1 Introduction
9.2 Adults
9.3 Pediatrics
10 America's Therapeutic Vaccines Market
11 Europe's Therapeutic Vaccines Market
12 Middle East and Africa's Therapeutic Vaccines Market
13 APAC's Therapeutic Vaccines Market
14 Competitive Landscape
14.1 Analyst Competitive Quadrant
14.2 Market Share Analysis
15 Company Profiles
15.1 Agenus, Inc.
15.2 Argos Therapeutic, Inc.
15.3 AstraZeneca PLC
15.4 Bavarian Nordic A/S
15.5 BioNTech SE
15.6 Celldex Therapeutic, Inc.
15.7 CSL Ltd.
15.8 Cytos Biotechnology AG
15.9 Dendreon Corp.
15.10 GlaxoSmithKline PLC
15.11 GSK, PLC
15.12 INOVIO Pharmaceuticals
15.13 Johnson & Johnson
15.14 Merck & Co. Inc.
15.15 Novartis AG
15.16 Panacea Biotec
15.17 Pfizer, Inc.
15.18 Phio Pharmaceuticals Corp.
15.19 Sanofi SA
15.20 Serum Institute of India Pvt. Ltd.
16 Appendix
16.1 Self-Assessment Form
For more information about this report visit https://www.researchandmarkets.com/r/dmonnt
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
